01:06 PM EDT, 09/09/2024 (MT Newswires) -- ArriVent BioPharma ( AVBP ) said Monday that interim data from phase 1b study of firmonertinib monotherapy in non-small cell lung cancer patients showed positive systemic and central nervous system responses as of June 20.

The proof-of-concept global study of firmonertinib was also generally well-tolerated with a profile consistent with previous data, the company said.

The treatment showed "promising" dose-dependent activity in patients in a broad range of EGFR PACC mutations in the first-line metastatic setting, ArriVent said.

The dose-dependent interim data strengthen firmonertinib's potential as an effective oral, chemotherapy-free treatment for a PACC mutant population, said ArriVent Chairman and Chief Executive Bing Yao.

Price: 28.09, Change: +0.07, Percent Change: +0.27